DNA ploidy in bronchopulmonary carcinoid tumours.

A Study of Biological Behavior Based on the Expression of a Proliferating Antigen in Neuroendocrine Tumors of the Digestive System

“…Because of that, it has been concluded that DNA analyses are not useful in the evaluation of their malignant behavior [15]. These observations are sup ported by several recent reports using flow cytometric DNA measurements [20,21], but is opposed by one investigation where the proportion of DNA aneuploidy in carcinoids was found to be 45% [22], The occurrence of diploid DNA stem cells in neuroendocrine tumors has been used for studies on cytologic tumor material to evalu ate the in vivo action of given cytotoxins on the different phases of the tumor cell cycle. After treatment with streptozotocin, for ex ample, an increase in the number of tetraploid cells has been noted [15].…”

Clinicopathologic and DNA Cytometric Analysis of Carcinoid Tumors of the Thymus

“…Aneuploidy has been found in 5 to 32% of typical carcinoids and in 16 to 79% of atypical carcinoids (14,(41)(42)(43)(44)(45) and is reported to be associated with a poor prognosis (43). However, not all aneuploid carcinoid tumors have such poor outcomes because Jones et al (43) reported that 58% of patients with aneuploid carcinoid tumors survived 5 years. In our study, aneuploidy was found in only one tumor.…”

“…Various studies reported results of DNA analysis in bronchial carcinoid tumors (14,(41)(42)(43)(44)(45). Aneuploidy has been found in 5 to 32% of typical carcinoids and in 16 to 79% of atypical carcinoids (14,(41)(42)(43)(44)(45) and is reported to be associated with a poor prognosis (43).…”

Apoptosis and expression of bcl‐2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung

“…12,13 DNA analysis in atypical carcinoid tumours revealed significantly more often aneuploidy and, within this entity, an aneuploid DNA content pursued a far more aggressive course than did their diploid counterparts. [14][15][16][17][18] With immunohistochemical methods an overexpression of the tumour suppressor gene p53 was not identifiable in pulmonary carcinoid tumours. [19][20][21] Furthermore infrequent mutations of the p53 gene were described in 20% of typical carcinoids, contrasting with the lack of mutations in atypical carcinoids.…”